Compare Msci Inc (MSCI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs GeneDx Holdings Corp — how do they compare? Msci Inc trades at $554.53 (market cap $40.32B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Msci Inc is far larger — about 15.6× GeneDx Holdings Corp's market cap, and Msci Inc pays a 1.48% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MSCI | WGS | |
|---|---|---|
Market Cap | $40.32B | $2.58B |
Sector | Financials | Technology |
52-Week High | $643.83 | $167.51 |
52-Week Low | $511.84 | $34.51 |
Enterprise Value | $46.48B | $2.61B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $551.39, down 3.77% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $3.13B in 2025 and a net income margin of 40.73%, though it faces a high P/E of 30.32. Recent developments include the acquisition of First Street and a strategic partnership with UBS, enhancing its private markets platform. Cash flow turned positive in 2025, but high debt levels and a negative equity position pose risks.
The outlook is mixed: analyst consensus is bullish with a $728.14 price target, but technical indicators signal caution. Upside potential hinges on continued earnings beats and revenue growth, while risks include market volatility and execution challenges. Investors should weigh strong profitability against valuation concerns and debt load.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
